瑞穗强调Zoryve的增长，Arcutis股价上涨18%

2024-08-24 01:36

Arcutis Biotherapeutics (NASDAQ:ARQT) is up ~18% in Friday trading after Mizuho issued a bullish note citing growth in prescriptions of the company's Zoryve (roflumilast) cream and foam for various skin conditions.
Analyst Uy Ear wrote that Zoryve recently had double-digit new prescription week-over-week growth, adding that this should eventually lead to an increase in overall prescriptions.
In Q2, Zorye foam for seborrheic dermatitis brought in revenue of $13.6M and $17.3M for Zoryve cream for plaque psoriasis.
In the quarter (ended June 30), total prescriptions for Zoryve increased 258% compared to the prior-year period and 42% compared to Q1.
As of the end of the quarter, Arcutis was reporting close to 10,000 weekly Zoryve prescriptions.
Year to date, Arcutis shares are up ~201%.

More on Arcutis Biotherapeutics